Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.

Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.

Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.

Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.

Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.

Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.

Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.

Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.

Abstract: Protocol status information is used to perform traffic filtering by dropping messages that are not consistent with the protocol status information. In one embodiment, a method involves comparing message information and protocol status information. The message information is associated with a first message. The protocol status information is obtained in response to one or more second messages, which are conveyed according to a protocol used to assign network addresses to clients. The method also involves determining whether to discard the first message, based on an outcome of the comparison of the message information and the protocol status information. For example, it can be determined that the first message should be discarded, if the message information does not match the protocol status information.

Abstract: Protocol status information is used to perform traffic filtering by dropping messages that are not consistent with the protocol status information. In one embodiment, a method involves comparing message information and protocol status information. The message information is associated with a first message. The protocol status information is obtained in response to one or more second messages, which are conveyed according to a protocol used to assign network addresses to clients. The method also involves determining whether to discard the first message, based on an outcome of the comparison of the message information and the protocol status information. For example, it can be determined that the first message should be discarded, if the message information does not match the protocol status information.

Abstract: A method for preparing hydrorefining catalyst comprises the following steps: (1) mixing an aqueous ammonia solution with a polyamine complexing agent to form a mixed solvent; (2) adding a cobalt salt to the mixed solvent, dissolving the cobalt salt, and then adding a molybdenum salt and optional salts of other active components, and dissolving them to prepare an impregnating solution; and (3) impregnating a support with the impregnating solution, followed by aging, drying, and activating the impregnated support to form a hydrorefining catalyst. The hydrorefining catalyst prepared by this method has good activity, selectivity and stability in use.

Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.

Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.

Abstract: The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.

Abstract: A method for using a deployable, small package acoustic transmitter device is taught, which serves as a standard acoustic source for on-vessel, in-mission field calibration purposes. The method involves deploying an acoustic transmitter device underwater to provide a predefined acoustic energy source for sonar array detection as well as periodic time-coded acoustic signal pulses for tracking and calibration of passive ranging.

Abstract: A method for preparing hydrorefining catalyst comprises the following steps: (1) mixing an aqueous ammonia solution with a polyamine complexing agent to form a mixed solvent; (2) adding a cobalt salt to the mixed solvent, dissolving the cobalt salt, and then adding a molybdenum salt and optional salts of other active components, and dissolving them to prepare an impregnating solution; and (3) impregnating a support with the impregnating solution, followed by aging, drying, and activating the impregnated support to form a hydrorefining catalyst. The hydrorefining catalyst prepared by this method has good activity, selectivity and stability in use.